drugset / Trial / NCT03146533
CD19 CART Cells for Patients With Relapse and Refractory CD19+ B-cell Lymphoma.
Phase 1/2
Unknown
20 enrolled
Shenzhen Second People's Hospital
The Beijing Pregene Science and Technology Company, Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a clinical study to observe the maximum tolerated dose (MTD) and the safety and feasibility of chimeric antigen receptor 19 (CD19 CART) cells in relapsed and refractory patients with CD19+ B cell lymphoma.
Timeline
- Start
- 2017-05
- Primary completion
- 2019-04
- Completion
- 2019-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD19 CAR-T | Cell therapy | — | — |
| Background | Cyclophosphamide | Other / unclassified | 800 mg/m2 | Intravenous |
| Background | Fludarabine | Small molecule | 30 mg/m2 | Intravenous |